Another study found that monocytes with JAK2V617F expressed a greater amount of CD25, an activate marker of monocytes than those with wild-type JAK2. Also, monocytes isolated from MPN patients with thrombotic history expressed a greater amount of CD25 compared with those isolated from MPN patients without thrombotic history (9). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.